Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

Texas MPN Workshop 2022 | Polycythemia vera: disease outcomes, unmet needs and therapeutic strategies

Jerry Spivak • 10 Nov 2022
Texas MPN Workshop 2022
Essential Thrombocythemia Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Hydroxyurea Ruxolitinib

Jerry Spivak, MD, Johns Hopkins University School of Medicine, Baltimore, MD, gives a presentation on disease outcomes, unmet needs and therapeutic strategies in polycythemia vera (PV) at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Jerry Spivak

Polycythemia vera: myths, mechanisms, and management
Jerry Spivak • 24 Nov 2022
Challenges in the treatment and management of ET and the need to improve therapeutic approaches 5:21
Challenges in the treatment and management of ET and the need to improve therapeutic approaches
Jerry Spivak • 26 Aug 2022
The need to improve diagnostic criteria in PV and other challenges in the field 6:04
The need to improve diagnostic criteria in PV and other challenges in the field
Jerry Spivak • 26 Aug 2022
The importance of patient perspectives during treatment journeys 2:04
The importance of patient perspectives during treatment journeys
Jerry Spivak • 26 Aug 2022

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals